The National Agency for Food and Drug Administration and Control (NAFDAC) has raised the alarm over “counterfeit Dostinex (0.5mg) tablets found in circulation.”
In a statement on Monday, the agency warned “healthcare providers, patients, and the public about the falsification and parallel importation of three batches of a NAFDAC-registered product: Dostinex 0.5mg Tablets.”
Citing American multinational pharmaceutical giant, Pfizer Nigeria Ltd, NAFDAC said “the Marketing Authorization Holder (MAH) of the products, has confirmed the presence of falsified and parallel unregistered imported versions of these products.”
“According to Pfizer Nigeria Ltd, the legitimate product has been registered but has not yet been imported into Nigeria.
“Dostinex 0.5 mg is a medication that reduces prolactin secretion, helping to alleviate symptoms caused by excess prolactin,” NAFDAC said.
Highlighting the risk of counterfeit Dostinex in circulation, the NAFDAC said “the potency of products is highly dependent on complying with regulatory requirements.”
It added, “Falsified, unlicensed, and unregistered medicines present significant risks to public health. Therefore, the quality, safety, and efficacy of these products cannot be guaranteed.”
